8-K: Medtronic Reports Strong FY26 Results, Highest Revenue Growth in 10 Years

Medtronic plc announced its fourth quarter and full year fiscal 2026 results, showcasing 8.4% reported revenue growth for the full year and delivering the highest annual revenue growth in a decade.

Summary

• Medtronic reported fourth quarter fiscal year 2026 revenue of $9.8 billion, a 9.9% increase as reported and 6.6% organically.
• Full year fiscal year 2026 revenue reached $36.4 billion, an 8.4% increase as reported and 5.8% organically.
• Non-GAAP diluted EPS for Q4 FY26 was $1.55, exceeding guidance.
• Full year non-GAAP diluted EPS was $5.53, a 0.7% increase.
• The company announced a dividend increase to $0.72 per share for Q1 FY27, marking the 49th consecutive annual increase.
• Medtronic filed a submission to the U.S. FDA for Hugo RAS and received FDA clearance for the Stealth AXiS Surgical System.
• Several M&A and venture capital transactions were completed or announced to strengthen portfolios and accelerate growth.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, exceeding guidance, and a consistent history of dividend increases, indicating financial health and shareholder returns.

Positives

• Achieved highest annual revenue growth in 10 years.
• Q4 revenue of $9.8 billion exceeded guidance.
• Full year revenue of $36.4 billion represents strong organic growth.
• Cardiac Ablation Solutions revenue increased 78% globally.
• Cardiovascular segment grew 10.1% in Q4.
• Medical Surgical segment reported strong performance, up 5.1% in Q4.
• Secured key FDA clearances and CE Mark for surgical systems.
• 49th consecutive year of dividend increases, with a new quarterly dividend of $0.72 per share.

Negatives

• FY26 non-GAAP operating margin decreased 130 basis points year-over-year.
• Q4 non-GAAP operating margin decreased 230 basis points year-over-year, impacted by MiniMed Blackstone payment and tariffs.
• FY26 non-GAAP diluted EPS on a constant currency basis decreased 2.0%.

Risks

• Risks related to competitive factors.
• Difficulties and delays inherent in the development, manufacturing, marketing, and sale of medical products.
• Government regulation.
• Geopolitical conflicts and changing global trade policies.
• Material acquisition and divestiture transactions.
• General economic conditions.

Future Outlook

For FY27, Medtronic is guiding to 6.75% to 7.25% organic revenue growth and diluted non-GAAP EPS in the range of $5.90 to $6.00, representing 6.7% to 8.5% growth.

Management Comments

• "Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor."
• "These results represent the compounding impact of deliberate choices we've made to strengthen our strategy, sharpen execution, and invest in the areas that will drive our future."
• "We saw continued strength in some of our largest businesses like CRM, CST and Surgical, and we are building momentum in our highest growth opportunities, such as Affera, Symplicity, Hugo, Altaviva and Stealth AXiS."
• "Together with the investments we're making in our pipeline, Medtronic is well positioned to deliver sustained growth and long-term value."
• "We are pleased to have delivered results ahead of expectations on both revenue and EPS."
• "As we look to FY27, we are entering the year with strong momentum, a resilient operating foundation, and a clear path to deliver durable growth."
• "With a uniquely robust pipeline, our tuck-in M&A and investment strategy activated, and continued financial discipline, we are poised to build on our FY26 performance."

Industry Context

StockSavvy.ai notes that Medtronic's reported revenue growth of 8.4% for FY26 surpasses the typical growth rates seen in the mature medical device industry, indicating strong execution and market positioning, particularly in high-growth segments.

Comparison to Industry Standards

• Medtronic's FY26 organic revenue growth of 5.8% is robust compared to the broader medical device industry, which often sees growth in the mid-single digits.
• The company's focus on high-growth areas like Cardiac Ablation Solutions (78% global growth) and robotic surgery (Hugo RAS filing) aligns with industry trends towards minimally invasive procedures and technological advancement.
• Competitors like Johnson & Johnson (MedTech segment) and Abbott Laboratories also focus on cardiovascular and neuromodulation, but Medtronic's specific segment growth rates, particularly in Cardiac Rhythm Management and Surgical Robotics, appear to be outperforming in certain areas.

Stakeholder Impact

• Shareholders: Benefit from a 49th consecutive annual dividend increase and potential share price appreciation due to strong financial performance.
• Employees: Continued investment in growth areas may lead to opportunities and job security.
• Customers: Access to innovative medical technologies and solutions, including FDA-cleared systems.
• Suppliers: Continued strong demand for products may benefit suppliers.

Next Steps

• Continue to execute on strategy and invest in high-growth opportunities.
• Advance pipeline development.
• Integrate completed M&A transactions (CathWorks) and pursue announced acquisitions (Scientia Vascular, SPR Therapeutics).
• Offer Medtronic ViaVerte system in Neuromodulation.
• Continue to develop and gain regulatory approval for new technologies like Hugo RAS.

Key Dates

Recommendation

The company demonstrated its strongest annual revenue growth in a decade, exceeded guidance for Q4 revenue and EPS, and continues its streak of dividend increases, signaling robust operational performance and a positive outlook for FY27. Strategic M&A and product clearances further bolster confidence.

Keywords

Medtronic, Healthcare Technology, Medical Devices, Earnings, Financial Results, Revenue Growth, FDA Clearance, Dividend